Medical/Pharmaceuticals
SK Biopharmaceuticals to Present Future Plan for Global Investors, Partners at 'SK Bio Night'
SK Inc.'s 1st SK Bio Night on the sidelines of J.P. Morgan Healthcare Conference offers a glimpse into the future of its global business in new drug, CDMO, biotech SK Biopharmaceuticals joins SK Inc.'s Bio Investment Center, SK pharmteco, or 'SK bio family,'for potential investment, partnerships...
2023-01-10 07:00
1853
SK Inc. hosts "SK Bio Night" in San Francisco to expand global partnerships
* SK to spark innovative ideas and identify new business opportunities by presenting its global strategy and growth roadmap to over 50 partners * Newly appointed executives to lead SK's biopharmaceutical businesses to attend the event * SK Inc. to promote the competitiveness of K-bio and pro...
2023-01-10 07:00
1693
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
U.S. now open for enrollment of rare, rapidly progressive Parkinsonian Disorder MELBOURNE, Australia and SAN FRANCISCO, Jan. 9, 2023 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying tre...
2023-01-09 23:25
2245
FlatTech LLC Receives Innovative Technology Contract from Vizient for EpiFaith(R) Syringe for safer epidurals
Contract awarded for products that bring improvement to health care industry
TAIPEI, Jan. 9, 2023 /PRNewswire/ -- FlatTech LLC announced its EpiFaith®
Syringe for epidural has received an Innovative Technology contract from
Vizient, Inc.
2023-01-09 21:00
2155
SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia
* The world-second developed shingles vaccine 'SKYZoster™' is approved by the National Pharmaceutical Regulatory Agency (NPRA) * SK biosciences plans to launch the zoster vaccine with proven efficacy and safety starting in Southeast Asian market SEOUL, South Korea, Jan. 9, 2023 /PRNewswire/ -...
2023-01-09 21:00
2285
Immorna Receives IND Clearance to Conduct a Phase 1 Study of JCXH-105, a Self-Replicating RNA-Based Shingles Vaccine
MORRISVILLE, N.C., Jan. 9, 2023 /PRNewswire/ -- Immorna, a rapidly expanding biotechnology company, focusing on the development of multi-platform RNA-based therapeutics and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) ap...
2023-01-09 20:00
1737
Jacobio Completes First Patient Dosage of Aurora A Inhibitor JAB-2485 in U.S
BEIJING and SHANGHAI and BOSTON, Jan. 8, 2023 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced it has completedthe first patient dosage of its in-house R&D drug candidate Aurora A Inhibitor JAB-2485 in a Phase I/IIa clinical trial for advanced solid tumour patients in U.S. JAB-2485 is a high...
2023-01-08 14:17
3412
Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US
PRINCETON, N.J., Jan. 7, 2023 /PRNewswire/ -- Fosun Pharma (600196.SH, 02196.HK) has recently entered into an exclusive license agreement with Shanghai Henlius Biotech, Inc. (2696.HK) for the commercialisation of Henlius independently developed anti-PD-1 monoclonal antibody (mAb) serplulimab inth...
2023-01-07 17:29
3769
Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD
Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ -- KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage biotechnology company dedicated to research, development, and commercialization of innovative medici...
2023-01-06 21:00
2045
Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)
MELBOURNE, Australia and SAN FRANCISCO, Jan. 6, 2023 /PRNewswire/ -- Alterity Therapeutics Limited ("Alterity" or the "Company") (ASX:ATH, NASDAQ:ATHE), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that its Board of D...
2023-01-06 20:25
3762
Double-blind period completes! Primary endpoint analysis of phase 3 clinical trial to be conducted for China's first hormone replacement treatment targeting hypoparathyroidism
Submission of NDA to the NMPA is planned within 2023 at the earliest SHANGHAI, Jan. 6, 2023 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, announced today that it has completed the double-blind period of PaTHway China Trial, a phase 3...
2023-01-06 18:00
1618
Standigm cited as 'Top 10 Generative AI-based startup based on VC Investment, 2019-2021' in Gartner® report
SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- Standigm
2023-01-05 22:00
1765
B dot Medical to Install Its First Practical Ultra-compact Proton Therapy System at Hospital in Tokyo
- Memorandum of Understanding Signed with Edogawa Hospital - TOKYO, Jan. 5, 2023 /PRNewswire/ -- B dot Medical Inc. has signed a memorandum of understanding with Edogawa Hospital inJapan for the installation of the company's first practical ultra-compact proton therapy system, which means the fi...
2023-01-05 15:00
1714
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
* Duality to grant license of DITAC (Duality Immune Toxin Antibody Conjugates) platform to Adcendo for its lead uPARAP ADC program * Duality to receive upfront payment, development, regulatory and commercial milestones, and tiered royalties * Collaboration based on synergies between Adcendo ...
2023-01-05 09:00
1303
Ascentage Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SUZHOU, China and ROCKVILLE, Md., Jan. 4, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its Chairman and CEO, Dr.Dajun Yang, has accep...
2023-01-05 09:00
2385
Innovent to Present at 41st Annual J.P. Morgan Healthcare Conference
ROCKVILLE, Md. and SUZHOU, China, Jan. 4, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, o...
2023-01-05 00:00
2776
Lunit to Supply AI Solution for Chest X-Ray Analysis to Albert Einstein, Latin America's Largest Hospital
* Lunit signed a software license agreement with the Hospital Israelita Albert Einstein,Latin America's top medical institution, to provide its AI-based chest x-ray solution * Under the agreement, Lunit will supply its AI solution for chest x-ray image analysis to the Hospital Israelita Alber...
2023-01-04 21:20
2457
OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors
NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneurRobert Forrester and venture capitalist Chau Khuong as independent ...
2023-01-04 21:00
1975
Waterdrop and Jemincare Collaborate on the "Digital Service Platform for CKD Patients"
BEIJING, Jan. 4, 2023 /PRNewswire/ -- Waterdrop and Jemincare recently reached a cooperation, according to which both sides will jointly launch the "Digital Service Platform for CKD Patients". Featuring both online and offline service modules ranging from follow-up visits and consultation with do...
2023-01-04 21:00
3024
Sihuan Pharmaceutical（0460.HK）: Huisheng Biopharmaceutical Successfully Completed the A + Round of Financing
Accelerating the Layout of Diabetes and Complications HONG KONG, Jan. 4, 2023 /PRNewswire/ -- Sihuan Pharmaceutical Holdings Group Co., Ltd. (the "Company" or "Sihuan Pharmaceutical", together with its subsidiaries, collectively referred to as the "Group"; stock code: 0460) is pleased to announc...
2023-01-04 15:52
3315
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8546
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7700